바이오어피니티 테크놀로지스(BIAF)는 NAS에 상장된 Healthcare · Diagnostics & Research 기업입니다. 현재가 $9.43 (+7.77%), 시가총액 $7.71M.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
바이오어피니티 테크놀로지스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
바이오어피니티 테크놀로지스의 현재 주가는 $9.43 (+7.77%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
바이오어피니티 테크놀로지스의 시가총액은 약 $7.71M입니다.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated…